Fast Vote Count Surprises and Delights Argentina
28.10.2019 21:42:00 EET | Business Wire | Press release
Argentina processed election results with record-breaking speed during its general elections thanks to the new system implemented in partnership with technology company Smartmatic. The vote was held on October 27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005666/en/
Telegram processing rates on election night, 2015 vs. 2019. (Photo: Business Wire)
Only three hours after voting ended, 70.48% of the tallying reports (called “telegrams” in Argentina) had been digitized, securely transmitted and uploaded into the system. By midnight, 96.08% of telegrams were processed.
Election observers representing the political parties closely monitored the entire process. The high level of transparency and speed with which the results were processed and published allowed the main candidates to publicly accept the outcomes shortly after results were announced.
“We are honored to have supported Argentine authorities for this important election by deploying Smartmatic’s unmatched technology. We were able to facilitate fast, accurate results that gave peace of mind to political parties and the country in general,” said Antonio Mugica, CEO of Smartmatic.
According to information released by election authorities, voter participation exceeded 80%. Voters chose among four candidates for head of government and six formulas for president and vice president. In eight provinces, 72 candidates vied for senate seats and 595 candidates competed to become deputies at the national level.
Smartmatic provided secure technology both for the digitation and transmission of telegrams, and for the consolidation and publication of results. Just as in the primaries held in August, telegrams were transmitted directly from over 10,000 voting centers to two consolidation centers. Approximately 1,700 operators at the consolidation centers transcribed and loaded into the system the information contained in the telegrams.
"Because of the speed and accuracy with which results were published, misinformation about the technology that had been widely distributed across social media and other news outlets fell flat and was easily discredited. Argentines today welcomed the innovations introduced by the authorities that make elections more efficient and more transparent," added Mugica.
Smartmatic participated in Argentina’s 2019 election cycle after winning two public bids in which international election technology companies competed.
It is anticipated that, as in the primaries, the provisional results will be an accurate reflection of the final vote count. In August, the difference between the provisional and final results was less than 1% in each of the Argentine provinces.
About Smartmatic
Smartmatic specializes in the design and deployment of election system technologies. As the global leader in providing secure, transparent, verifiable voting systems, Smartmatic is setting the standard for election integrity worldwide including encrypted results transmission, paper ballot back-up, extensive auditing and the first use of blockchain technology to secure online voting. Additional information about Smartmatic can be found at: www.smartmatic.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005666/en/
Contact information
Smartmatic
Mrs. Samira Saba, +1-561-862-0747
Marketing and Communications Director
Communications@smartmatic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom